Divergent susceptibilities to AAV-SaCas9-gRNA vector-mediated genome-editing in a single-cell-derived cell population

ObjectiveRecombinant adeno-associated virus (AAV)-based vectors are characterized by their robust and safe transgene delivery. The CRISPR/Cas9 and guide RNA (gRNA) system present a promising genome-editing platform, and a recent development of a shorter Cas9 enzyme from Staphylococcus aureus (SaCas9) allows generation of high titer single AAV vectors which carry both saCas9- and gRNA-expression cassettes. Here, we used two AAV-SaCas9 vectors with distinct GFP-targeted gRNA sequences and determined the impact of AAV-SaCas9-gRNA vector treatment in a single cell clone carrying a GFP-expression cassette.ResultsOur results showed comparable GFP knockout efficiencies (40–50%) upon a single low-dose infection. Three consecutive transductions of 25-fold higher doses of vectors showed 80% GFP knockout efficiency. To analyze the “AAV-SaCas9-resistant cell population”, we sorted the residual GFP-positive cells and assessed their permissiveness to super-infection with two AAV-Cas9-GFP vectors. We found the sorted cells were significantly more resistant to the GFP knockout mediated by the same AAV vector, but not by the other GFP-targeted AAV vector. Our data therefore demonstrate highly efficient genome-editing by the AAV-SaCas9-gRNA vector system. Differential susceptibilities of single cell-derived cells to the AAV-SaCas9-gRNA-mediated genome editing may represent a formidable barrier to achieve 100% genome editing efficiency by this vector system.

[1]  Y. Kudva,et al.  Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy , 2013, Disease Models & Mechanisms.

[2]  Eli J. Fine,et al.  DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.

[3]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[4]  J. Keith Joung,et al.  731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .

[5]  John J. Wyrick,et al.  Nucleosomes Inhibit Cas9 Endonuclease Activity in Vitro. , 2015, Biochemistry.

[6]  Jin-Soo Kim,et al.  Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases , 2014, Genome research.

[7]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[8]  Seung Woo Cho,et al.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease , 2013, Nature Biotechnology.

[9]  G. Church,et al.  Cas9 as a versatile tool for engineering biology , 2013, Nature Methods.

[10]  Michael Hallek,et al.  Recent developments in adeno‐associated virus vector technology , 2008, The journal of gene medicine.

[11]  Morgan L. Maeder,et al.  Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy. , 2015, Human gene therapy.

[12]  D. Segal,et al.  How specific is CRISPR/Cas9 really? , 2015, Current opinion in chemical biology.

[13]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[14]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[15]  Y. Ikeda,et al.  An siRNA Screen Identifies the U2 snRNP Spliceosome as a Host Restriction Factor for Recombinant Adeno-associated Viruses , 2015, PLoS pathogens.

[16]  Paul Enríquez CRISPR-Mediated Epigenome Editing , 2016, The Yale journal of biology and medicine.

[17]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[18]  Li-juan Ji,et al.  CRISPR-Cas9: a new and promising player in gene therapy , 2015, Journal of Medical Genetics.

[19]  Feng Zhang,et al.  Applications of CRISPR–Cas systems in neuroscience , 2015, Nature Reviews Neuroscience.